/
Respiratory
Moderate to Severe COPD
2
Pipeline Programs↗
3
Active Trials↗
10
Companies Involved↗
Moderate to Severe COPD is an early-stage landscape with 2 programs across 10 companies. The most active players are AstraZeneca, Aer Therapeutics. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Phase 31
Approved
No programs
Analysis
Trial Status
21
clinical trials
Completed16 · 76%
Not yet recruiting2 · 10%
Terminated2 · 10%
Recruiting1 · 5%
Clinical Trials
Trial Activity
21 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)